Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{173697,
        author = {Pranali Sandip Band and Apali Ajay Jain and Riya Warshe and Nikita Nagnath Musale and Tejaswini Suresh Patle and Aditya Pise and Sejal Kanhaiya Agrawal and Pratik D. Dhokne},
        title = {INNOVATIVE DRUG TARGETS AND TREATMENTS FOR TYPES OF HYPERLIPIDEMIA- A REVIEW},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {10},
        pages = {1110-1120},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=173697},
        abstract = {An increase in one or more of the plasma lipids, such as triglycerides, cholesterol, cholesterol esters, phospholipids, and/or plasma lipoproteins, such as very low-density lipoprotein and low-density lipoprotein, combined with a decrease in high-density lipoprotein levels, is known as hyperlipidemia. One of the main risk factors for cardiovascular illnesses is this increase in plasma lipids. At the expense of serious liver and muscle adverse effects, statins and fibrates continue to be the principal anti-hyperlipidemic medications for the treatment of increased plasma cholesterol and triglycerides, respectively. The forms of hyperlipidemias, lipid metabolism, therapies, and novel therapeutic targets for managing high lipid profiles are the primary topics of this review. Numerous substances, including diacyl glycerol, squalene epoxidase inhibitors, and lanosterol synthase inhibitors},
        keywords = {Cholesterol, Hyperlipidemia, Medications, Therapies},
        month = {March},
        }